Get the Stockscreener App
12.45
1.22%
0.15
After Hours:
12.69
0.24
+1.93%
Cogent Biosciences Inc stock is traded at $12.45, with a volume of 3.47M.
It is up +1.22% in the last 24 hours and up +72.20% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$12.30
Open:
$12.05
24h Volume:
3.47M
Relative Volume:
1.30
Market Cap:
$1.42B
Revenue:
-
Net Income/Loss:
$-242.30M
P/E Ratio:
-5.0202
EPS:
-2.48
Net Cash Flow:
$-192.10M
1W Performance:
+8.26%
1M Performance:
+72.20%
6M Performance:
+51.83%
1Y Performance:
+43.27%
1-Day Range:
$12.01
$12.74
1-Week Range:
$11.60
$12.97
52-Week Range:
$3.72
$12.97
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
12.45 | 1.60B | 0 | -242.30M | -192.10M | -2.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
What drives Cogent Biosciences Inc. stock priceOutstanding investment returns - jammulinksnews.com
Is Cogent Biosciences Inc. a good long term investmentMarket-beating performance - jammulinksnews.com
What analysts say about Cogent Biosciences Inc. stockOutstanding investment returns - jammulinksnews.com
Cogent Biosciences (NASDAQ:COGT) Given New $22.00 Price Target at Citigroup - MarketBeat
3 Stocks With Sky-High Overbought Signals: QuantumScape, Opendoor, Cogent Flash RSI Red Flags - Benzinga
When (COGT) Moves Investors should Listen - news.stocktradersdaily.com
Cogent Biosciences Inc. Stock Analysis and ForecastOutperformance with explosive growth - Autocar Professional
Cogent Biosciences (COGT) Target Price Raised by Citigroup | COG - GuruFocus
Cogent Biosciences stock hits 52-week high at 12.66 USD By Investing.com - Investing.com South Africa
Cogent Biosciences stock hits 52-week high at 12.66 USD - Investing.com
Blueprint Medicines' (BPMC) Ayvakit Faces Competition from Cogent Biosciences | BPMC Stock News - GuruFocus
Blueprint Medicines' (BPMC) Ayvakit Faces Competition from Cogen - GuruFocus
Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating - MSN
Cogent Biosciences: Analyst Maintains Buy Rating Amid Promising Trials and Strategic Advantages - AInvest
Day 11 of Gains Streak for Cogent Biosciences Stock with 67% Return (vs. 52% YTD) [7/16/2025] - Trefis
10 Best Small-Cap Stocks to Buy According to Billionaires - Insider Monkey
COGT Stock Up 62% after 10-Day Win Streak - Trefis
Mintz Advises on Cogent Biosciences’ $230 Million Public Offering - Mintz
Press Release: Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock - 富途牛牛
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - MSN
Cogent Biosciences (NASDAQ:COGT) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says - MarketBeat
Guggenheim Reiterates "Buy" Rating for Cogent Biosciences with $17 Price Target - AInvest
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $22.00 at HC Wainwright - MarketBeat
Cogent Biosciences Closes $230 Million Upsized Stock Offering - MarketScreener
Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Cogent Biosciences Announces Closing of Upsized Public - GlobeNewswire
Cogent Biosciences Secures Massive $230M Funding for Bezuclastinib Drug Development - Stock Titan
Cogent Biosciences’ Mysterious 5.6% Surge: What’s Behind the Move? - AInvest
Cogent Biosciences' 8% Surge: Unraveling the Mystery Behind the Spike - AInvest
Cogent Biosciences(COGT) Soars 6.34% on Phase III Success - AInvest
Form 424B5 Cogent Biosciences, Inc. - StreetInsider
Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results (COGT) - Seeking Alpha
Cogent Biosciences: Drug Trial Triumph Sparks Stock Surge - StocksToTrade
A Quick Look at Today's Ratings for Cogent Biosciences(COGT.US), With a Forecast Between $17 to $25 - 富途牛牛
Cogent Biosciences slips after upsized $200 mln equity offering - TradingView
Cogent Biosciences Prices $200 Million Stock Offering - MarketScreener
Cogent Biosciences (COGT) Prices $200M Public Offering at $9 Per Share - GuruFocus
Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges - NewsBreak: Local News & Alerts
Cogent Biosciences Secures Massive $200M Funding to Accelerate Bezuclastinib Development - Stock Titan
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock - The Manila Times
Cogent Biosciences announces pricing of upsized public offering of shares of common stock - MarketScreener
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock | COGT Stock News - GuruFocus
Cogent Biosciences stock falls on $150 million share offering By Investing.com - Investing.com India
After-hours movers: Mobileye, RxSight, Cogent Biosciences By Investing.com - Investing.com Canada
Cogent Biosciences (COGT) Sees Positive Analyst Action with Rais - GuruFocus
Cogent's Funding to Propel Bezuclastinib Development | COGT Stoc - GuruFocus
Cogent Biosciences' $150M Offering: A Risky Gamble or a Strategic Bet on Breakthrough Science? - AInvest
Cogent Biosciences stock falls on $150 million share offering - Investing.com Australia
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):